AU2001231000A1 - Dry powder formulations of antihistamine for nasal administration - Google Patents

Dry powder formulations of antihistamine for nasal administration

Info

Publication number
AU2001231000A1
AU2001231000A1 AU2001231000A AU3100001A AU2001231000A1 AU 2001231000 A1 AU2001231000 A1 AU 2001231000A1 AU 2001231000 A AU2001231000 A AU 2001231000A AU 3100001 A AU3100001 A AU 3100001A AU 2001231000 A1 AU2001231000 A1 AU 2001231000A1
Authority
AU
Australia
Prior art keywords
antihistamine
dry powder
nasal administration
powder formulations
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001231000A
Inventor
Solomon S. Steiner
Bryan R Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Pharmaceutical Discovery Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Discovery Corp filed Critical Pharmaceutical Discovery Corp
Publication of AU2001231000A1 publication Critical patent/AU2001231000A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
AU2001231000A 2000-01-19 2001-01-19 Dry powder formulations of antihistamine for nasal administration Abandoned AU2001231000A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17684500P 2000-01-19 2000-01-19
US60176845 2000-01-19
PCT/US2001/001870 WO2001052818A1 (en) 2000-01-19 2001-01-19 Dry powder formulations of antihistamine for nasal administration

Publications (1)

Publication Number Publication Date
AU2001231000A1 true AU2001231000A1 (en) 2001-07-31

Family

ID=22646091

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001231000A Abandoned AU2001231000A1 (en) 2000-01-19 2001-01-19 Dry powder formulations of antihistamine for nasal administration

Country Status (3)

Country Link
US (2) US7833549B2 (en)
AU (1) AU2001231000A1 (en)
WO (1) WO2001052818A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
KR20050044523A (en) * 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 Pharmaceutical compositions in particulate form
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
PL1786784T3 (en) 2004-08-20 2011-04-29 Mannkind Corp Catalysis of diketopiperazine synthesis
EP2322180B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Diketopiperazine salts for drug delivery
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
HUE031470T2 (en) 2004-11-24 2017-07-28 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods of use thereof
RU2390325C2 (en) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Method for preparing drug based on higher affinity of active agents to crystalline microparticle surfaces
RU2403059C2 (en) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Method of improving pharmaceutical properties of particles, containing diketopiperazine and active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US8636001B2 (en) 2008-06-13 2014-01-28 Mannkind Corporation Dry powder inhaler and system for drug delivery
DK2609954T3 (en) 2008-06-20 2022-02-14 Mannkind Corp Interactive device for real-time imaging of inhalation performance
TWI614024B (en) 2008-08-11 2018-02-11 曼凱公司 Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
CN102647979B (en) 2009-06-12 2015-03-04 曼金德公司 Diketopiperazine particles with defined specific surface areas
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
EP2582421A1 (en) 2010-06-21 2013-04-24 MannKind Corporation Dry powder drug delivery system and methods
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
US10092660B2 (en) 2011-04-25 2018-10-09 Stc.Unm Solid compositions for pharmaceutical use
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (en) 2011-10-24 2014-07-23 曼金德公司 Methods and compositions for treating pain
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
SG11201507564PA (en) 2013-03-15 2015-10-29 Mannkind Corp Microcrystalline diketopiperazine compositions and methods
MX2020009878A (en) 2013-07-18 2022-07-27 Mannkind Corp Heat-stable dry powder pharmaceutical compositions and methods.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
CN107929925B (en) * 2017-12-13 2020-06-09 杨兆辉 Breathe special medicine feeding device of internal medicine

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
IT1130924B (en) 1980-03-06 1986-06-18 Secifarma Spa PROCEDURE FOR THE PREPARATION OF MICRONIZED SPIRONOLACTONE
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
EP0187433B1 (en) * 1983-08-01 1990-12-27 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
ES2053678T3 (en) * 1987-11-13 1994-08-01 Asta Medica Ag PROCEDURE FOR PREPARING AN AZELASTIN CONTENT MEDICATION FOR NASAL AND / OR EYE APPLICATION.
DE3744329A1 (en) 1987-12-28 1989-07-06 Schwarz Pharma Gmbh METHOD FOR THE PRODUCTION OF AT LEAST ONE ACTIVE AGENT AND A TRAITER COMPRISING PREPARATION
US5141273A (en) * 1989-10-11 1992-08-25 The Budd Company Molded composite bumper
GB9000459D0 (en) * 1990-01-09 1990-03-07 James Michael H Medicaments for treatment of airborne allergies
WO1993013752A1 (en) 1992-01-21 1993-07-22 Sri International Improved process for preparing micronized polypeptide drugs
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
IS1796B (en) 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE4329446A1 (en) 1993-09-01 1995-03-02 Basf Ag Process for the production of finely divided color or active substance preparations
FR2722984B1 (en) 1994-07-26 1996-10-18 Effik Lab PROCESS FOR THE PREPARATION OF DRY PHARMACEUTICAL FORMS AND THE PHARMACEUTICAL COMPOSITIONS THUS PRODUCED
SE9403846D0 (en) 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
SE9803770D0 (en) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections

Also Published As

Publication number Publication date
US20080038358A1 (en) 2008-02-14
US7833549B2 (en) 2010-11-16
US7833550B2 (en) 2010-11-16
US20020009418A1 (en) 2002-01-24
WO2001052818A1 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
AU2001231000A1 (en) Dry powder formulations of antihistamine for nasal administration
AU2002333644A1 (en) Dry powder medicament formulations
HUP0300593A3 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
AU762322C (en) Novel galenic formulations of meloxicam for oral administration
AU2002352974A1 (en) Formulations for oral administration of cromolyn sodium
WO2003002136A3 (en) Stable formulation of modified glp-1
AU2001230892A1 (en) Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
AU2003296897A1 (en) Pharmaceutical formulations of camptothecine derivatives
AU2001289102A1 (en) Topical formulations for delivery of interleukin-11
AU1131102A (en) Medicinal aerosol formulations
AU2001243611A1 (en) Stabilized dry powder formulations
AU2001287977A1 (en) Controlled release formulations for oral administration
AU2001284444A1 (en) Preparations for oral administration
AU6715600A (en) Pharmaceutical formulations
AU2001258395A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU9416201A (en) Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
AU2001284763A1 (en) Preparation of risperidone
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU1732401A (en) Medicinal compositions for oral use